Outlook Therapeutics, Inc. Overview
Pro stress-test →Outlook Therapeutics is a clinical-stage biopharmaceutical company developing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for retinal indications including wet age-related macular degeneration. The company represents a high-risk bet on regulatory approval and market penetration in ophthalmic therapeutics.
Strategic Profile
Pro stress-test →The company is working to develop and launch ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications including wet AMD, DME and BRVO. Outlook Therapeutics has entered into a strategic commercialization agreement with Cencora to expand reach for connecting to retina specialists and their patients.
Competitive Landscape
Pro stress-test →ONS-5010 competes in the wet AMD treatment space where multiple anti-VEGF therapies are already approved and commercialized. Key competitors include Regeneron's Eylea and Novartis's Lucentis, which have established market presence. Outlook's differentiation depends on achieving FDA approval for the first ophthalmic bevacizumab formulation.
Industry Context
Outlook Therapeutics, Inc. operates in Biopharmaceutical/Ophthalmology Therapeutics.
Key facts
Founded: 2010 · Headquarters: Iselin, New Jersey, United States · Employees: Unknown · Revenue: Minimal/Pre-revenue · Market cap: $34.8M